Summary of the Research Topic: This article collection sheds light on the pivotal roles played by RNA modifications and dysregulated non-coding RNAs—such as long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs)—in various human diseases, including cancers (osteosarcoma, non-small cell lung cancer, cholangiocarcinoma), autoimmune disorders (myasthenia gravis), liver diseases (primary sclerosing cholangitis), and inflammatory bowel diseases (IBD: ulcerative colitis and Crohn’s disease). The research highlights RNA modifications such as N6-methyladenosine (m6A), pseudouridine (?), 5-methylcytosine (m5C), among others, emphasizing their significant influence on gene expression and potential therapeutic implications. Importantly, the compilation documents potential clinical applications, emphasizing how RNA-binding proteins, alternative splicing events (particularly of CD44 isoforms), and non-coding RNAs can serve as diagnostic biomarkers, prognostic indicators, and therapeutic targets. Collectively, these reviews showcase the complexity and importance of post-transcriptional regulation in disease etiology and progression, underscoring the enormous potential for RNA-based biomarkers and therapeutic strategies.
---------------------------------------------------------------------
Research Topic Description: Chronic diseases such as cancer, arthritis, and fibrosis are the leading causes of death and disability worldwide. Recent findings have highlighted that RNA processing is systematically altered in chronic disease. Cellular RNA processing is elaborately regulated by both cis-acting elements and trans-acting factors, while mutations or dysregulations of RNA splicing or modification determinants are widely observed, eventually remodeling the transcriptomics in chronic diseases. Importantly, accumulating evidence supports the role of new RNA species, including circular RNAs (circRNAs), and tRNA-derived small RNAs (tsRNAs) in promoting disease evolution. Consequently, the focus on uncovering the clinical relevance of RNA biogenesis defects is currently growing and multiple interference or replacement strategies toward RNA processing have been demonstrated to amplify therapeutic efficiency.
In this special issue, we introduce both established and emerging roles for RNA processing in controlling RNA abundance and fate. we debate how altered processing or activity of cellular RNAs allows for chronic diseases. These alterations can be illustrated in a way of gene mutations or varied expression in RNA processors, or in a way of dysregulated RNAs themselves. Such RNA molecules may involve mRNAs, miRNAs, and lncRNAs, as well as less understood RNA entities, such as tsRNAs and circRNAs. Given that cellular RNAs also receive abundant structural or chemical modifications and rely on the modifications for their biogenesis and function, we also discuss the modification landscape underlying RNA behavior. Better characterization of the widespread alteration in RNA processing may provide a wealth of new opportunities for disease management. Hopefully, the articles gathered in this special issue will have excellent visibility to a broader reading community and inspire more remarkable work that further advances this field.
This issue features a series of cutting-edge reviews, mini-reviews, and original research articles focusing on, but not limited to the following topics:
• Regulation of RNA biogenesis pathways in cancer, fibrosis, or arthritis.
• How disturbances in the spliceosome or splicing factors drive aberrant splicing and expression of certain RNAs.
• The advances in the identification, characterization, and regulatory network of various RNAs (e.g. lncRNAs, circRNAs, and mRNAs) in chronic disease contexts as well as their utility as potential indicators or therapeutic agents.
• How the representative RNA modifications, such as methylation, the uridine-to-pseudouridine (?), and adenosine-to-inosine transition regulate disease progression through remodeling transcriptomics.
Summary of the Research Topic: This article collection sheds light on the pivotal roles played by RNA modifications and dysregulated non-coding RNAs—such as long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs)—in various human diseases, including cancers (osteosarcoma, non-small cell lung cancer, cholangiocarcinoma), autoimmune disorders (myasthenia gravis), liver diseases (primary sclerosing cholangitis), and inflammatory bowel diseases (IBD: ulcerative colitis and Crohn’s disease). The research highlights RNA modifications such as N6-methyladenosine (m6A), pseudouridine (?), 5-methylcytosine (m5C), among others, emphasizing their significant influence on gene expression and potential therapeutic implications. Importantly, the compilation documents potential clinical applications, emphasizing how RNA-binding proteins, alternative splicing events (particularly of CD44 isoforms), and non-coding RNAs can serve as diagnostic biomarkers, prognostic indicators, and therapeutic targets. Collectively, these reviews showcase the complexity and importance of post-transcriptional regulation in disease etiology and progression, underscoring the enormous potential for RNA-based biomarkers and therapeutic strategies.
---------------------------------------------------------------------
Research Topic Description: Chronic diseases such as cancer, arthritis, and fibrosis are the leading causes of death and disability worldwide. Recent findings have highlighted that RNA processing is systematically altered in chronic disease. Cellular RNA processing is elaborately regulated by both cis-acting elements and trans-acting factors, while mutations or dysregulations of RNA splicing or modification determinants are widely observed, eventually remodeling the transcriptomics in chronic diseases. Importantly, accumulating evidence supports the role of new RNA species, including circular RNAs (circRNAs), and tRNA-derived small RNAs (tsRNAs) in promoting disease evolution. Consequently, the focus on uncovering the clinical relevance of RNA biogenesis defects is currently growing and multiple interference or replacement strategies toward RNA processing have been demonstrated to amplify therapeutic efficiency.
In this special issue, we introduce both established and emerging roles for RNA processing in controlling RNA abundance and fate. we debate how altered processing or activity of cellular RNAs allows for chronic diseases. These alterations can be illustrated in a way of gene mutations or varied expression in RNA processors, or in a way of dysregulated RNAs themselves. Such RNA molecules may involve mRNAs, miRNAs, and lncRNAs, as well as less understood RNA entities, such as tsRNAs and circRNAs. Given that cellular RNAs also receive abundant structural or chemical modifications and rely on the modifications for their biogenesis and function, we also discuss the modification landscape underlying RNA behavior. Better characterization of the widespread alteration in RNA processing may provide a wealth of new opportunities for disease management. Hopefully, the articles gathered in this special issue will have excellent visibility to a broader reading community and inspire more remarkable work that further advances this field.
This issue features a series of cutting-edge reviews, mini-reviews, and original research articles focusing on, but not limited to the following topics:
• Regulation of RNA biogenesis pathways in cancer, fibrosis, or arthritis.
• How disturbances in the spliceosome or splicing factors drive aberrant splicing and expression of certain RNAs.
• The advances in the identification, characterization, and regulatory network of various RNAs (e.g. lncRNAs, circRNAs, and mRNAs) in chronic disease contexts as well as their utility as potential indicators or therapeutic agents.
• How the representative RNA modifications, such as methylation, the uridine-to-pseudouridine (?), and adenosine-to-inosine transition regulate disease progression through remodeling transcriptomics.